Tobacco regulatory science: research to inform regulatory action at the Food and Drug Administration's Center for Tobacco Products.

The U.S. Food and Drug Administration (FDA) promotes the development of regulatory science to ensure that a strong evidence base informs all of its regulatory activities related to the manufacture, marketing, and distribution of tobacco products as well as public education about tobacco product constituents and effects. Toward that end, the FDA's Center for Tobacco Products (CTP) provides funding for research studies with scientific aims that fall within its defined regulatory authority. However, given their traditional biomedical focus on basic and applied research, some researchers may not understand the principles of regulatory science or the types of studies CTP funds. The purpose of this paper is (1) to clarify the definition of regulatory science as a distinct scientific discipline, (2) to explore the role of tobacco regulatory science in order to help researchers understand the parameters and types of research that can be funded by CTP, and (3) to describe the types of research efforts that will inform the FDA's public health framework for tobacco product regulation.

[1]  C. Husten,et al.  Understanding the Tobacco Control Act: efforts by the US Food and Drug Administration to make tobacco-related morbidity and mortality part of the USA's past, not its future , 2013, The Lancet.

[2]  C. Backinger,et al.  The Food and Drug Administration's regulation of tobacco: the Center for Tobacco Products' Office of Science. , 2012, American journal of preventive medicine.

[3]  Brett Norman The Food and Drug Administration gets new tools to spur regulatory science. , 2012, Health affairs.

[4]  M. Miller,et al.  Impact of regulatory science on global public health , 2012, The Kaohsiung journal of medical sciences.

[5]  J. L. Goodman Transforming Regulatory Science 2012: Making a Difference , 2012, Clinical pharmacology and therapeutics.

[6]  R. O’Connor Postmarketing surveillance for "modified-risk" tobacco products. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[7]  C. Backinger,et al.  Research priorities and infrastructure needs of the Family Smoking Prevention and Tobacco Control Act: science to inform FDA policy. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[8]  J. Difranza Research opportunities concerning youth and the Family Smoking Prevention and Tobacco Control Act. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[9]  K. Ribisl Research gaps related to tobacco product marketing and sales in the Family Smoking Prevention and Tobacco Control Act. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[10]  D. Hatsukami,et al.  Tobacco and nicotine product testing. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[11]  D. Hammond Tobacco packaging and labeling policies under the U.S. Tobacco Control Act: research needs and priorities. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[12]  S. Hecht,et al.  Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[13]  Elizabeth Sukkar Lack of investment in regulatory science is part of “innovation gap,” believes FDA commissioner , 2011, BMJ : British Medical Journal.

[14]  J. Henningfield Tobacco psychopharmacology and public health policy: it takes a community. , 2011, Experimental and clinical psychopharmacology.

[15]  M. Hamburg,et al.  Advancing Regulatory Science , 2011, Science.

[16]  Garrett Fitzgerald,et al.  Regulatory Science: What It Is and Why We Need It , 2011, Clinical pharmacology and therapeutics.

[17]  M. Hamburg Shattuck lecture. Innovation, regulation, and the FDA. , 2010, The New England journal of medicine.